ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

4:30PM-6:00PM: Abstract Number: 2249

Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study

Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD

4:30PM-6:00PM: Abstract Number: 2256

Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-5:30PM: Abstract Number: 2233

Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia

Abstracts: Fibromyalgia and Other Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 2242

Metabolomics-based Identification of Metabolic Dysfunction in Inclusion Body Myositis

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 2257

MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-5:30PM: Abstract Number: 2234

Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis

Abstracts: Fibromyalgia and Other Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 2243

Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

4:30PM-6:00PM: Abstract Number: 2238

Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 2248

Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort

Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD

4:30PM-6:00PM: Abstract Number: 2247

Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions

Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

4:30PM-6:00PM: Abstract Number: 2237

Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 2251

Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD

4:30PM-6:00PM: Abstract Number: 2258

Relative Frequencies of the Spectrum of MRI Lesions in the Sacroiliac Joints of Healthy Individuals and Patients with Non-Specific Back Pain: What Is the Impact of Increasing Age?

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-6:00PM: Abstract Number: 2246

Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes

Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

4:30PM-6:00PM: Abstract Number: 2244

Salient Coping Strategies Among Youth with Chronic Musculoskeletal Pain

Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].